person · Reporting owner

Vessey Rupert

Disclosed activity across 5 companies

Tapewire entity: 15357
SEC CIK: 0001677618

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-TECHNE CorpTECH · Entity 3479	Director	October 30, 2025	November 03, 2025
BRISTOL MYERS SQUIBB COBMY · Entity 1662	EVP & President, Research	May 03, 2023	May 04, 2023
Generate Biomedicines, Inc.GENB · Entity 1553	Director	February 26, 2026	March 02, 2026
Juno Therapeutics, Inc.JUNO · Entity 168572	Director	April 13, 2017	April 19, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-TECHNE Corp

Report date October 30, 2025 · Filed November 03, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,987	Reported balance After 2025-10-30 transaction · row 1 1 source row Row 1 · 2025-10-30 · Grant · Acquired 1,640 · Balance 10,987
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30	Direct	3,777	Reported balance After 2025-10-30 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-10-30 · Grant · Acquired 3,777 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24	Direct	8,044	Reported balance Holding disclosure · report date 2025-10-30 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 8,044
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.32 · Expires 2029-06-30	Direct	2,352	Reported balance Holding disclosure · report date 2025-10-30 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 2,352
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29	Direct	6,028	Reported balance Holding disclosure · report date 2025-10-30 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 6,028
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28	Direct	2,532	Reported balance Holding disclosure · report date 2025-10-30 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 2,532
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27	Direct	3,460	Reported balance Holding disclosure · report date 2025-10-30 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 3,460
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26	Direct	3,937	Reported balance Holding disclosure · report date 2025-10-30 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 3,937
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24	Direct	3,511	Reported balance Holding disclosure · report date 2025-10-30 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 3,511

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

BRISTOL MYERS SQUIBB CO

Report date May 03, 2023 · Filed May 04, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	47,751	Reported balance After 2023-05-03 transaction · row 1 1 source row Row 1 · 2023-05-03 · Sale · Disposed 50,385 · Balance 47,751 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBMS Savings and Investment Program	655.73	Reported balance Holding disclosure · report date 2023-05-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 655.73 F2: Based on recent 401(k) plan statement.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

F2: Based on recent 401(k) plan statement.

Generate Biomedicines, Inc.

Report date February 26, 2026 · Filed March 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25	Direct	29,561	Reported balance After 2026-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Juno Therapeutics, Inc.

Report date April 13, 2017 · Filed April 19, 2017

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-11-20 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2019-11-20 · Grant · Acquired 8,634 · Balance 22,812 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 13,906 · Balance 36,718 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 24,209 · Balance 60,927 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 60,927 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Common StockSEC Table I · non-derivative	Indirect401(k) Plan	Reported balance After 2019-11-20 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 613 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.57 · Expires 2025-02-02	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 19,142 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.90 · Expires 2025-05-04	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $132.56 · Expires 2025-07-27	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.08 · Expires 2025-11-09	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.80 · Expires 2026-02-01	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 2,344 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.97 · Expires 2026-05-02	Direct	Reported balance After 2019-11-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-20 · Disposition to issuer · Disposed 9,680 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.69 · Expires 2026-08-01	Direct	Reported balance After 2019-11-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.18 · Expires 2026-10-31	Direct	Reported balance After 2019-11-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-11-20 · Disposition to issuer · Disposed 31,210 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.18 · Expires 2027-01-30	Direct	Reported balance After 2019-11-20 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $124.06 · Expires 2027-05-01	Direct	Reported balance After 2019-11-20 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.41 · Expires 2027-07-31	Direct	Reported balance After 2019-11-20 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.97 · Expires 2027-10-30	Direct	Reported balance After 2019-11-20 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2019-11-20 · Disposition to issuer · Disposed 26,308 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.26 · Expires 2028-01-29	Direct	Reported balance After 2019-11-20 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.13 · Expires 2028-05-08	Direct	Reported balance After 2019-11-20 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30	Direct	Reported balance After 2019-11-20 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.43 · Expires 2028-10-29	Direct	Reported balance After 2019-11-20 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2019-11-20 · Disposition to issuer · Disposed 5,756 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2019-11-20 · Disposition to issuer · Disposed 3,120 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2019-11-20 · Disposition to issuer · Disposed 9,271 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2019-11-20 · Disposition to issuer · Disposed 5,794 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2019-11-20 · Disposition to issuer · Disposed 37,660 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F3: This option was fully exercisable.

F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	45,028	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 26 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,028 Underlying: Common Stock, $0.10 par value · 45,028 shares Expires 2022-03-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F14 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F14 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	70,048	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 25 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,048 Underlying: Common Stock, $0.10 par value · 70,048 shares Expires 2022-03-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F13 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on March 1, 2020. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F13 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	10,777	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 24 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,777 Underlying: Common Stock, $0.10 par value · 10,777 shares Expires 2022-02-04 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F12 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on February 4, 2020. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F12 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on February 4, 2020. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	17,245	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 23 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,245 Underlying: Common Stock, $0.10 par value · 17,245 shares Expires 2021-05-08 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F11 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on May 8, 2019. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F11 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on May 8, 2019. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	25,865	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 22 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,865 Underlying: Common Stock, $0.10 par value · 25,865 shares Expires 2021-03-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F10 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F10 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	5,804	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 21 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 Underlying: Common Stock, $0.10 par value · 5,804 shares Expires 2020-10-30 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F9 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on October 30, 2018. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F9 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on October 30, 2018. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	10,707	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 20 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,707 Underlying: Common Stock, $0.10 par value · 10,707 shares Expires 2020-05-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_price: The restricted stock unit vests in three equal installments beginning on May 1, 2018. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on May 1, 2018. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	16,059	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 19 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,059 Underlying: Common Stock, $0.10 par value · 16,059 shares Expires 2020-03-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F7 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F7 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	33,957	$0.00 Strike: $38.41	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 18 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,957 Underlying: Common Stock, $0.10 par value · 33,957 shares Expires 2028-10-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	33,958	$0.00 Strike: $47.81	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 17 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,958 Underlying: Common Stock, $0.10 par value · 33,958 shares Expires 2028-07-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	33,958	$0.00 Strike: $44.70	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 16 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,958 Underlying: Common Stock, $0.10 par value · 33,958 shares Expires 2028-05-08 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	21,173	$0.00 Strike: $55.52	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 15 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,173 Underlying: Common Stock, $0.10 par value · 21,173 shares Expires 2028-01-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	48,932	$0.00 Strike: $54.29	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 14 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,932 Underlying: Common Stock, $0.10 par value · 48,932 shares Expires 2027-10-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	21,288	$0.00 Strike: $72.42	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 13 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,288 Underlying: Common Stock, $0.10 par value · 21,288 shares Expires 2027-07-31 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	21,288	$0.00 Strike: $66.35	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 12 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,288 Underlying: Common Stock, $0.10 par value · 21,288 shares Expires 2027-05-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	24,134	$0.00 Strike: $60.53	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 11 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,134 Underlying: Common Stock, $0.10 par value · 24,134 shares Expires 2027-01-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	58,050	$0.00 Strike: $54.94	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 10 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,050 Underlying: Common Stock, $0.10 par value · 58,050 shares Expires 2026-10-31 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	24,134	$0.00 Strike: $61.34	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 9 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,134 Underlying: Common Stock, $0.10 par value · 24,134 shares Expires 2026-08-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	18,003	$0.00 Strike: $56.44	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 8 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,003 Underlying: Common Stock, $0.10 par value · 18,003 shares Expires 2026-05-02 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	4,359	$0.00 Strike: $54.20	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 7 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,359 Underlying: Common Stock, $0.10 par value · 4,359 shares Expires 2026-02-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	5,843	$0.00 Strike: $61.01	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 6 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2025-11-09 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	5,843	$0.00 Strike: $70.89	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 5 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2025-07-27 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	5,843	$0.00 Strike: $58.78	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2025-05-04 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	35,794	$0.00 Strike: $63.41	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 3 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,794 Underlying: Common Stock, $0.10 par value · 35,794 shares Expires 2025-02-02 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	613	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: 613 F3 · shares: Based on a plan statement as of the end of the most recent fiscal quarter. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:42 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	14,178	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,178 F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person. F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:38 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	45,029	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000036 · wf-form4a_157810186432684.xml · derivative · entry 3 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,029 Underlying: Common Stock, $0.10 par value · 45,029 shares Expires 2021-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:38 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	25,866	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000036 · wf-form4a_157810186432684.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,866 Underlying: Common Stock, $0.10 par value · 25,866 shares Expires 2020-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:38 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	16,060	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000036 · wf-form4a_157810186432684.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,060 Underlying: Common Stock, $0.10 par value · 16,060 shares Expires 2019-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · derivative.exercise_price: Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person as well as the correct expiration date for a few of the awards. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F5 · derivative.exercise_price: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	5,369	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001257 · form4-11042019_041114.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,369 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	2,644	$108.03	$285,631.32	Disclosure SEC source: 0001415889-19-001257 · form4-11042019_041114.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,178 Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	5,369	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001257 · form4-11042019_041114.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
October 24, 2019 Filed Oct 28, 2019 21:04 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Option (right to buy) · Derivative	2,011	$0.00 Strike: $201.64	$0.00	Disclosure SEC source: 0001624404-19-000014 · edgar.xml · derivative · entry 3 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document
October 24, 2019 Filed Oct 28, 2019 21:04 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantCommon Stock	495	$0.00	$0.00	Disclosure SEC source: 0001624404-19-000014 · edgar.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642 Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:49 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to buy) · Derivative	588	$0.00 Strike: $209.26	$0.00	Disclosure SEC source: 0001562180-19-003807 · primarydocument.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588 Underlying: Common Stock · 588 shares Expires 2029-10-25 F1 · derivative.exercise_date: The option vests on 6/30/2029. Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:49 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantCommon Stock	147	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003807 · primarydocument.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147 Read SEC document
July 01, 2019 Filed Apr 11, 2025 20:37 UTC Amendment	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to Buy) · Derivative	588	$0.00 Strike: $209.26	$0.00	Disclosure SEC source: 0001062993-25-007369 · form4a.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588 Underlying: Common Stock · 588 shares Expires 2029-06-30 Read SEC document
May 02, 2019 Filed May 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	6,731	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000508 · form4-05062019_040514.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,731 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. Read SEC document
May 02, 2019 Filed May 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	2,531	$95.21	$240,976.51	Disclosure SEC source: 0001415889-19-000508 · form4-05062019_040514.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,453 Read SEC document
May 02, 2019 Filed May 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	6,731	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000508 · form4-05062019_040514.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
March 01, 2019 Filed Mar 5, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	37,660	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000251 · form4-03052019_040320.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,660 Underlying: Common Stock · 37,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document
February 04, 2019 Filed Feb 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	5,794	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-19-000134 · form4-02062019_040206.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,794 Underlying: Common Stock · 5,794 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document
December 16, 2018 Filed Dec 18, 2018 18:43 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	5,350	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001774 · form4-12182018_031253.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. Read SEC document
December 16, 2018 Filed Dec 18, 2018 18:43 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	2,634	$68.20	$179,638.80	Disclosure SEC source: 0001415889-18-001774 · form4-12182018_031253.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,253 Read SEC document
December 16, 2018 Filed Dec 18, 2018 18:43 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	5,350	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001774 · form4-12182018_031253.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
October 29, 2018 Filed Oct 31, 2018 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	18,257	$0.00 Strike: $71.43	$0.00	Disclosure SEC source: 0001415889-18-001568 · form4-10312018_041007.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,257 Underlying: Common Stock · 18,257 shares Expires 2028-10-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 29, 2019. Read SEC document
July 30, 2018 Filed Aug 1, 2018 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	18,257	$0.00 Strike: $88.91	$0.00	Disclosure SEC source: 0001415889-18-001200 · form4-08012018_040801.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,257 Underlying: Common Stock · 18,257 shares Expires 2028-07-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019. Read SEC document
May 08, 2018 Filed May 17, 2018 16:09 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	9,271	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-18-000764 · form4-05172018_010507.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,271 Underlying: Common Stock · 9,271 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document
May 08, 2018 Filed May 17, 2018 16:09 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (Right to Buy) · Derivative	18,257	Not disclosed Strike: $83.13	Not disclosed	Disclosure SEC source: 0001415889-18-000764 · form4-05172018_010507.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,257 Underlying: Common Stock · 18,257 shares Expires 2028-05-08 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal installments, commencing on May 8, 2019. Read SEC document
May 04, 2018 Filed May 8, 2018 16:36 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionPerformance Stock Unit · Derivative	2,344	$0.00	$0.00	Disclosure SEC source: 0001415889-18-000697 · form4-05082018_010520.xml · derivative · entry 7 VESSEY RUPERT · CIK 0001677618 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The performance stock units granted to the reporting person on May 4, 2015, vested and settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each performance stock unit represents a contingent right to one share of the Company's common stock. F6 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The performance stock units granted to the reporting person on May 4, 2015, vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: The performance stock units granted to the reporting person on May 4, 2015, vested and settled for shares of the Company's common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.